Company news
Hansa Biopharma Ab (OMXSTO:HNSA) news
Hansa Biopharma Ab news releases on 6ix. Latest, Sep 24, 2026: Hansa Biopharma Announces New Board Appointments
Press releases & updates
Hansa Biopharma Announces New Board Appointments
September 24, 2026
Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)
September 22, 2026
Hansa Biopharma Announces Confidential Submission of Draft Registration Statement to the SEC to allow for a potential Listing of ADSs in the United States
August 21, 2026
Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results
July 22, 2026
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
July 1, 2026
Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for `What's Hot, What's New' Plenary at ATC 2026
June 24, 2026
Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer
June 15, 2026
Hansa Biopharma appoints Fredrik Röök as VP Business Development
June 10, 2026
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
June 1, 2026
Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation
May 27, 2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
May 25, 2026
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix from Hansa Biopharma for EUR115 million
May 20, 2026
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
May 19, 2026
Hansa Biopharma Report First Quarter 2026 Financial Results
April 23, 2026
Hansa Biopharma to host Q1 2026 interim results conference call
April 8, 2026
Hansa Biopharma publishes 2025 Annual and Sustainability Reports
March 26, 2026
PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
March 4, 2026
Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
February 18, 2026
Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
February 11, 2026
KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer
February 10, 2026
Hansa Biopharma has won the 2025 SwedenBIO Award
January 22, 2026
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
December 19, 2025
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
October 30, 2025
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
October 29, 2025
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
October 10, 2025
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
September 24, 2025
Hansa Biopharma announces key executive appointments to support continued growth
July 29, 2025
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
July 17, 2025
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
July 8, 2025
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
June 30, 2025
Hansa Biopharma to attend BIO International Convention
June 11, 2025
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
June 9, 2025
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
May 14, 2025
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
May 13, 2025